Pricing Log in Create free account
Saturday 17 October 2026 Export LITS’s income statement to Excel — free account

Lite Strategy, Inc.

LITS Healthcare Biotechnology

Lite Strategy, Inc.’s revenue for fiscal 2024 (year ended June 2024) was $65.3 million, up 33.8% from fiscal 2023. In the quarter to June 2026, EPS fell 11.0% and free cash flow grew 179.3%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

1.14 0.06 −5.00%
Market cap
$36.3M
P/E
0.0×
Fwd P/E
−0.5×
Dividend yield
—
F-score
5/9
Altman Z
−8.07
Beneish M
n/a
Dividend safety
n/a
Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.14
Total sells 0.95
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy 1 1 — — — — — 1 — — — —
Sell — 1 — — — — — — — — — —
Insider Ownership 13.28%

Capital & Financial Ratios $m

Market Cap 36.34
Revenue 105.38
Net Income (71.15)
Free Cash Flow (104.08)
Net Debt (5.71)
Current Ratio 5.74 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (0.46) (negative: loss-making)
P/S ratio 0.37
P/B ratio 0.95
Past 5Y EPS Growth —
This Y EPS Growth (335.21%) (below 0%: weak)
Next Y EPS Growth 34.80% (at or above 15%: strong)
Next Y revenue growth (90.43%) (below 0%: weak)
Next 5Y EPS Growth (0.10%) (below 0%: weak)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.3×, against a ten-year median of 0.5×; over the ten years it ranged from −2.9× in 2022 to 79.9× in 2018.
P/S against its own 10 years 21.13%
10-year low 10-year high
P/B against its own 10 years 31.26%
10-year low 10-year high
EV/Sales against its own 10 years 15.25%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2024 Powerpack
2023 0.00
1.75
2022 Powerpack
2021 Powerpack
2020 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 2026
Cash 101 38 18 6
Receivables 0 — — —
Inventory — — — —
Other — — — —
108 41 18 6
2023 2024 2025 2026
Payables 6 3 0 0
ST’ Debt — — — —
Other — — — —
20 8 1 1

Compound Annual Growth %

10y 5y 3y
Sales — 67.75% 23.34%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (0.01%) (3.39%) 19.12%

Revenue $m

Sep Dec Mar Jun Year
’26 — — — — —
’24 65 — — — 65
’23 9 33 6 1 49
’22 8 12 10 11 41
’21 7 13 8 7 35
’20 1 1 1 24 28
’19 0 2 1 1 5
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 (5) (2) (2) (1) (9)
’25 (11) (4) (3) (2) (21)
’24 (18) (11) (3) (18) (50)
’23 (15) (14) (12) (11) (52)
’22 (8) (9) (17) (16) (49)
’21 (9) 4 (16) (11) (32)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 (105) (2) 0 2 (104)
’25 (11) (4) (3) (2) (21)
’24 (18) (11) (3) (18) (50)
’23 (15) (14) (12) (11) (53)
’22 (8) (9) (17) (16) (49)
’21 (10) 4 (16) (11) (33)
Fiscal quarters ending in the months shown.

EPS $

Sep Dec Mar Jun Year
’26 — — — — —
’26 (0.12) (0.82) (0.66) (0.45) (2.06)
’25 (1.20) (0.40) (0.39) (0.40) (2.39)
’24 8.46 (1.66) (1.37) (2.76) 2.67
’23 (2.40) 1.60 (2.32) (1.51) (4.78)
’22 (3.07) (1.80) (1.40) (2.40) (10.00)
’21 0.12 (1.40) (5.60) (1.39) (7.22)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to June

Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Trend 2027e 2028e 2029e
Price, $
Price, $ Low 28.00 36.40 28.80 14.40 45.60 4.20 4.00 2.30 1.30 0.69

Analyst estimates 2027–2029

Powerpack
High 65.20 102.80 68.20 89.20 91.60 56.00 7.97 6.26 9.00 1.65
People
People Employees 25 32 40 51 76 102 46 28 4 5
Revenue/emp, $m 0.93 0.05 0.12 0.54 0.46 0.40 1.06 2.33 0.00 0.00
Income, $m
Income, $m Revenue 23 2 5 28 35 41 49 65 — —
Gross margin, % 78.49 (108.57) 13.27 90.38 95.95 100.00 100.00 100.00 — —
EBT 3 (40) (17) (47) (41) (54) (32) 18 (16) (71)
EBT margin, % 11.49 (2,470.22) (342.18) (169.95) (118.71) (133.80) (65.22) 27.23 0.00 0.00
Net income 3 (40) (17) (47) (41) (54) (32) 18 (16) (71)
Depreciation 0 0 0 0 0 0 0 11 0 —
Per share, $
Per share, $ Revenue 12.63 0.78 1.38 6.09 6.18 6.54 7.33 9.80 0.00 0.00
Earnings 1.40 (19.40) (4.80) (10.20) (9.00) (8.80) (4.78) 2.67 (2.39) (2.06)
Cash flow 1.89 (10.15) (8.27) 7.52 (5.68) (7.83) (7.88) (7.58) (3.13) (0.26)
Capex (0.03) 0.00 (0.06) (0.20) (0.13) (0.08) (0.01) 0.00 0.00 (2.75)
Free cash flow 1.87 (10.15) (8.33) 7.33 (5.81) (7.91) (7.88) (7.58) (3.13) (3.01)
Book value 27.62 24.36 13.47 16.92 8.79 8.42 3.70 4.96 2.54 1.20
Shares, m 2 2 4 5 6 6 7 7 7 35
Valuation, ×
Valuation, × P/E 39.83 0.00 0.00 0.00 0.00 0.00 0.00 1.07 — —
P/S 3.78 102.43 36.47 13.55 9.22 1.87 0.90 0.18 — —
P/B 1.73 3.29 3.74 4.88 6.48 1.45 1.78 0.58 — —
EV/Sales 1.48 39.09 21.32 6.97 4.81 (1.90) (1.16) (0.18) — —
EV/FCF 10.02 (3.01) (3.53) 5.80 (5.12) 1.57 1.08 0.38 — —
Cash, $m
Cash, $m Operating cash flow 3 (21) (29) 34 (32) (49) (52) (50) (21) (9)
Capex 0 — 0 (1) (1) 0 0 0 0 (95)
Free cash flow 3 (21) (30) 33 (33) (49) (53) (50) (21) (104)
Balance, $m
Balance, $m Working capital 50 96 68 195 145 143 87 32 17 5
Total debt — — — — 8 10 13 — — —
Net debt (54) (103) (74) (183) (153) (153) (101) (38) (18) (6)
Shareholders’ equity 51 50 48 77 49 52 25 33 17 42
Returns, %
Returns, % ROA 5.19 (49.97) (17.96) (32.27) (21.53) (30.95) (21.32) 21.92 (53.45) (233.37)
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 (115.85)
ROE 5.77 (79.11) (34.19) (75.48) (65.30) (106.90) (82.66) 61.68 (63.84) (243.02)
Negative figures in brackets.

All 10 years →

Fiscal years to Jun 2024 · latest quarter Sep 2023 · fundamentals updated 30 Sep 2026

Charts ten years each

Lite Strategy, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
LBPS 4D pharma PLC Sponsored ADR $37.2M — (loss-making) — +41.64% (above 0%: growing) n/m −16,367.69% (below 0%: shrinking) 0.00% 0.00% Compare
EXOZ eXoZymes Inc. $37.1M — (loss-making) — — n/m −3.25% (below 0%: shrinking) — 0.00% Compare
FLNA Cassava Sciences, Inc. $36.8M — (loss-making) — +1,328.04% (above 0%: growing) n/m +21.65% (above 0%: growing) 0.00% 0.00% Compare
LITS Lite Strategy, Inc. $36.3M — (loss-making) — (loss-making) +647.96% (above 0%: growing) n/m +179.28% (above 0%: growing) 0.00% 0.00%
EDSA Edesa Biotech, Inc. $36.1M — (loss-making) — (loss-making) −99.88% (below 0%: shrinking) n/m −81.24% (below 0%: shrinking) 0.00% 0.00% Compare
NNVC NanoViricides, Inc. $35.0M — (loss-making) — — n/m −23.94% (below 0%: shrinking) 0.00% 0.00% Compare
LIANY LianBio Sponsored ADR $34.2M 0.0× — — n/m +1,107.59% (above 0%: growing) 0.00% 0.00% Compare
CRVO CervoMed Inc. $34.0M — (loss-making) — (loss-making) −99.60% (below 0%: shrinking) n/m −6.20% (below 0%: shrinking) 100.00% 0.00% Compare
IRLA Quince Therapeutics, Inc. $33.8M — (loss-making) — — n/m −63.65% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $35.5M — — −28.98% — −15.07% 0.00% 0.00%

All 614 Biotechnology stocks →

Lite Strategy, Inc. (LITS) key facts

  • Strength: Lite Strategy, Inc.’s revenue for fiscal 2024 (year ended June 2024) was $65.3 million, up 33.8% from fiscal 2023.
  • Lite Strategy, Inc. (LITS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, LITS traded at $1.14, a market capitalization of $36.3 million.
  • Return on equity was −243.0% and debt-to-equity 0.00.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −8.07 (distress zone) for fiscal 2024.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Sep 30, 2026.

Lite Strategy, Inc. (LITS) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/LITS · Data as of Sep 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com